You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape

  • Authors: Richard B. Warren, MD, PhD
  • CPD Released: 10/28/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/28/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US dermatologists, pediatricians, and primary care physicians.

The goal of this activity is to highlight the impact of psoriasis on patients' lives, review treatment goals and recommendations for psoriasis, summarize key data on interleukin (IL)-17 inhibitors, and provide case-based discussion on the use of IL-17 inhibitors in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of moderate to severe psoriasis on patients' lives 
    • Key clinical data for IL-17 family inhibitors in moderate to severe psoriasis 
  • Demonstrate greater confidence in their ability to
    • Personalize patient care in moderate to severe psoriasis


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Richard B. Warren, MD, PhD

    Consultant Dermatologist
    Salford Royal NHS Foundation Trust
    Director of Dermatopharmacology Unit
    The University of Manchester
    Manchester, United Kingdom

    Disclosures

    Disclosure: Richard B. Warren, MD, PhD, has the following relevant financial relationships: 
    Served as an advisor or consultant for: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; DiCE Molecules; Eli Lilly and Company; Janssen Pharmaceuticals; Leo Pharma; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.; UNION  
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Almirall Hermal GmbH; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Leo Pharma; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc. 
    Received grants for clinical research from: AbbVie Inc.; Almirall Hermal GmbH; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Leo Pharma; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc. 
    Owns stock, stock options, or bonds from: AbbVie Inc. Almirall Hermal GmbH; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Leo Pharma; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.

Editor

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

Content Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape

Authors: Richard B. Warren, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 10/28/2021

Valid for credit through: 10/28/2022

processing....

Commentaire d'expert en français

Ce commentaire fait partie d’une activité de formation plus vaste. Après la participation, prière de retourner à  Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape  pour accéder à l’ensemble du contenu de formation relié. 

« Return to: Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape